CClinicalTrials.gg
WithdrawnNCT03441022Updated Sep 14, 2021

Continuous Data Collection and Analysis for Stroke Prevention Using a Wearable Sensor

An interventional study of Amiigo Watch Only and Amiigo Watch + BodyGuardian in Atrial Fibrillation, sponsored by Mayo Clinic. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-14.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Prevention

Why this study was withdrawn
Unable to obtain equipment from Sponsor to be able to proceed with the study.
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether a wristband that detects your pulse can detect your heart rate and rhythm similar to electrocardiograms (ECG).

Read the detailed description

The purpose of this study is to determine whether a wristband that detects your pulse can detect your heart rate and rhythm similar to electrocardiograms (ECG). These wristbands detect your pulse based on a technique called "photoplethysmography," (PPG). PPG is a common method in which an individual's pulse is detected based on a light signature interpreted by the wristband. Most commercially available heart rate monitors use PPG to determine your heart rate, but the accuracy is variable.

02

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Cardioversion
  • BodyGuardian
  • Amiigo Wristband
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Male or female 18 years of age or older with a primary diagnosis of atrial fibrillation
  2. Willing and able to provide informed consent and follow the study protocol
  3. Clinically indicated planned restoration of normal rhythm

Exclusion criteria

Exclusion Criteria:

  1. Unable to provide informed consent
  2. Unable to follow the study protocol
  3. Women who are pregnant
  4. Subjects with implantable devices (only if participating in phase 2-BodyGuardian processes/testing)
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Cardioversion

    Amiigo watch during atrial fibrillation cardioversion. Optional sub-study: additional 30 days wearing Amiigo watch as well as BodyGuardian device.

    Device: Amiigo Watch Only · Device: Amiigo Watch + BodyGuardian

Interventions

  • DeviceAmiigo Watch Only

    Subjects will be asked to wear a wrist band with capabilities to detect their heart rate or rhythm on the basis of PPG on either wrist around the time of their cardioversion procedure. Data will be acquired from the wrist band at the same time as the electrocardiogram (ECG) monitor to which subjects are hooked up for the purposes of the cardioversion.

    Also known as: Cardioversion

  • DeviceAmiigo Watch + BodyGuardian

    Subjects will be sent home after the cardioversion with a 30 day heart monitor called the BodyGuardian. This device continuously monitors their heart rate and rhythm and they will wear this on the chest. Subjects will also wear the wrist monitor over the same 30 day period.

    Also known as: Cardioversion plus 30 days

05

What researchers measure

Primary outcomes

  1. Watch Accuracy during Cardioversion

    Determine whether the R-R interval estimate from artifact-free non-invasive photoplethysmography sample waveform segments is a reasonable basis for a atrial fibrillation (AF) detection algorithm as compared to a gold standard measurement from ECG in the acute cardioversion setting

    Time frame: Duration of cardioversion procedure

  2. Watch Accuracy compared to BodyGuardian

    Determine the accuracy of ambulatory photoplethysmography for detection of heart rhythm when compared with a wearable clinically available 30 day monitor (BodyGuardian) in terms of accuracy of AF detection.

    Time frame: 30 days

06

Study locations

No study locations are listed for this record.

07

References and documents

08

Registry details

Key details

Study ID
NCT03441022
Lead sponsor
Mayo Clinic
Collaborators
Koronis Biomedical Technologies, National Institute on Aging (NIA)
Responsible party
Suraj Kapa (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Feb 22, 2018
Start date
Jul 15, 2021 (estimated)
Primary completion
Aug 2021 (estimated)
Completion
Aug 2021 (estimated)
Last update
Sep 14, 2021

Study contacts

Suraj Kapa, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion